Paraneoplastic Atypical Parkinsonism with Anti-CRMP5 Antibodies and Severe Caudate and Putaminal Hypometabolism on 18-Fluorodeoxyglucose Positron Emission Tomography of the Brain

Movement Disorders Clinical Practice

Volumn 4, Issue 2, 2017, Pages 263-265

  Yap, Siew Mei ^a   Lynch, Tim ^a   MacMahon, Peter ^a   Murray, Brian ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

18 fluorodeoxyglucose positron emission tomography (18FDG PET) brain; caudate and putamen; collapsin response mediator protein 5 (CRMP5); paraneoplastic Parkinsonism

Indexed keywords

AMPHIPHYSIN; ANTICOLLAPSIN RESPONSE MEDIATOR PROTEIN 5 ANTIBODY; CARBOPLATIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN G; LEVODOPA; TRANSCRIPTION FACTOR SOX1; UNCLASSIFIED DRUG;

AGED; ARTICLE; ATROPHY; BRAIN METABOLISM; CASE REPORT; CAUDATE NUCLEUS; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; ELECTROENCEPHALOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEMALE; HOARSENESS; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; LEUKOCYTE COUNT; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC NEUROPATHY; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SLOWNESS; SMALL CELL LUNG CANCER; URINARY URGENCY; WESTERN BLOTTING;

EID: 85040687185     PISSN: None     EISSN: 23301619     Source Type: Journal    
DOI: 10.1002/mdc3.12370     Document Type: Article

References (9)

1. Barton B, Zauber SE, Goetz CG. Movement disorders caused by medical disease. Semin Neurol 2009;29:97–110.
2. Tada S, Furuta M, Fukada K, et al. Severe parkinsonism associated with anti-CRMP5 antibody-positive paraneoplastic neurological syndrome and abnormal signal intensity in the bilateral basal ganglia [published online ahead of print 15 September 2015]. J Neurol Neurosurg Psychiatry 2016; doi: 10.1136/jnnp-2015-311569.
3. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146–154.
4. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135–1140.
5. Schottlaender LV, Polke JM, Ling H, et al. Analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism [serial online]. Neurobiol Aging 2015;36:1221.e1–1221.e6.
6. Leypoldt F, Wandinger KP. Paraneoplastic neurological syndromes. Clin Exp Immunol 2014;175:336–348.
7. McLaughlin D, Vidaki M, Karagogeos D. Localization of CRMP5 mRNA by in situ hybridisation during development of the mouse forebrain. Neurosci Lett 2008;432:117–120.
8. Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of movement disorders. Ann NY Acad Sci 2011;1228:93–108.
9. Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 2008;10:131–137.